These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 17763273

  • 1. No effect of tocolytic therapy with atosiban on maternal serum interleukin-6 and tumor necrosis factor-alpha in threatened preterm labor.
    Vitoratos N, Kountouris A, Makrakis E, Papadias K, Creatsas G.
    J Matern Fetal Neonatal Med; 2007 Oct; 20(10):725-8. PubMed ID: 17763273
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Atosiban versus usual care for the management of preterm labor.
    Husslein P, Cabero Roura L, Dudenhausen JW, Helmer H, Frydman R, Rizzo N, Schneider D.
    J Perinat Med; 2007 Oct; 35(4):305-13. PubMed ID: 17614750
    [Abstract] [Full Text] [Related]

  • 4. Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women.
    Shim JY, Park YW, Yoon BH, Cho YK, Yang JH, Lee Y, Kim A.
    BJOG; 2006 Nov; 113(11):1228-34. PubMed ID: 16978233
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical practice evaluation of atosiban in preterm labour management in six European countries.
    Husslein P, Roura LC, Dudenhausen J, Helmer H, Frydman R, Rizzo N, Schneider D, TREASURE study group.
    BJOG; 2006 Dec; 113 Suppl 3():105-10. PubMed ID: 17206976
    [Abstract] [Full Text] [Related]

  • 7. Maternal serum tumor necrosis factor-alpha in patients with preterm labor.
    Gücer F, Balkanli-Kaplan P, Yüksel M, Yüce MA, Türe M, Yardim T.
    J Reprod Med; 2001 Mar; 46(3):232-6. PubMed ID: 11304864
    [Abstract] [Full Text] [Related]

  • 8. Association between serum tumor necrosis factor-alpha and corticotropin-releasing hormone levels in women with preterm labor.
    Vitoratos N, Papadias K, Makrakis E, Christodoulakos G, Panoulis K, Creatsas G.
    J Obstet Gynaecol Res; 2006 Oct; 32(5):497-501. PubMed ID: 16984517
    [Abstract] [Full Text] [Related]

  • 9. [Clinical experience of using oxytocin antagonist atosiban in the rescue therapy of preterm labour].
    Tan JP, Chen H, Du BJ, Liu YL, Wang YH, Zhang JP.
    Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):81-4. PubMed ID: 18683742
    [Abstract] [Full Text] [Related]

  • 10. [Effectiveness and safety of atosiban vs. pulsatile administration of fenoterol in the treatment of preterm labour].
    Nonnenmacher A, Hopp H, Dudenhausen J.
    Z Geburtshilfe Neonatol; 2009 Oct; 213(5):201-6. PubMed ID: 19856243
    [Abstract] [Full Text] [Related]

  • 11. Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy.
    Richter ON, Dorn C, van de Vondel P, Ulrich U, Schmolling J.
    Arch Gynecol Obstet; 2005 Jun; 272(1):26-30. PubMed ID: 15909190
    [Abstract] [Full Text] [Related]

  • 12. Atosiban and nifedipine in acute tocolysis: a comparative study.
    Al-Omari WR, Al-Shammaa HB, Al-Tikriti EM, Ahmed KW.
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 128(1-2):129-34. PubMed ID: 16446025
    [Abstract] [Full Text] [Related]

  • 13. The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study.
    European Atosiban Study Group.
    Acta Obstet Gynecol Scand; 2001 May; 80(5):413-22. PubMed ID: 11328217
    [Abstract] [Full Text] [Related]

  • 14. Mid-pregnancy maternal plasma levels of interleukin 2, 6, and 12, tumor necrosis factor-alpha, interferon-gamma, and granulocyte-macrophage colony-stimulating factor and spontaneous preterm delivery.
    Curry AE, Vogel I, Drews C, Schendel D, Skogstrand K, Flanders WD, Hougaard D, Olsen J, Thorsen P.
    Acta Obstet Gynecol Scand; 2007 May; 86(9):1103-10. PubMed ID: 17712652
    [Abstract] [Full Text] [Related]

  • 15. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue.
    Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille JC, Tabor B, Perry KG, Varner M, Goodwin TM, Lane R, Smith J, Shangold G, Creasy GW.
    Am J Obstet Gynecol; 2000 May; 182(5):1173-83. PubMed ID: 10819855
    [Abstract] [Full Text] [Related]

  • 16. Randomized trial of oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of spontaneous preterm labor in Taiwanese women.
    Lin CH, Lin SY, Shyu MK, Chen SU, Lee CN.
    J Formos Med Assoc; 2009 Jun; 108(6):493-501. PubMed ID: 19515630
    [Abstract] [Full Text] [Related]

  • 17. Effect of an oxytocin receptor antagonist (atosiban) on uterine electrical activity.
    Hadar E, Melamed N, Aviram A, Raban O, Saltzer L, Hiersch L, Yogev Y.
    Am J Obstet Gynecol; 2013 Oct; 209(4):384.e1-7. PubMed ID: 23727522
    [Abstract] [Full Text] [Related]

  • 18. Preterm labor is induced by intraamniotic infusions of interleukin-1beta and tumor necrosis factor-alpha but not by interleukin-6 or interleukin-8 in a nonhuman primate model.
    Sadowsky DW, Adams KM, Gravett MG, Witkin SS, Novy MJ.
    Am J Obstet Gynecol; 2006 Dec; 195(6):1578-89. PubMed ID: 17132473
    [Abstract] [Full Text] [Related]

  • 19. Treatment of preterm labor with the oxytocin antagonist atosiban: a double-blind, randomized, controlled comparison with salbutamol.
    French/Australian Atosiban Investigators Group.
    Eur J Obstet Gynecol Reprod Biol; 2001 Oct; 98(2):177-85. PubMed ID: 11574128
    [Abstract] [Full Text] [Related]

  • 20. Maternal plasma cytokines in early- and mid-gestation of normal human pregnancy and their association with maternal factors.
    Curry AE, Vogel I, Skogstrand K, Drews C, Schendel DE, Flanders WD, Hougaard DM, Thorsen P.
    J Reprod Immunol; 2008 Apr; 77(2):152-60. PubMed ID: 17692390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.